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Abstract
Background: Emerging evidence implicates altered gene expression within skeletal muscle in the pathogenesis of Kennedy
disease/spinal bulbar muscular atrophy (KD/SBMA). We therefore broadly characterized gene expression in skeletal muscle
of three independently generated mouse models of this disease. The mouse models included a polyglutamine expanded
(polyQ) AR knock-in model (AR113Q), a polyQ AR transgenic model (AR97Q), and a transgenic mouse that overexpresses
wild type AR solely in skeletal muscle (HSA-AR). HSA-AR mice were included because they substantially reproduce the KD/
SBMA phenotype despite the absence of polyQ AR.
Methodology/Principal Findings: We performed microarray analysis of lower hindlimb muscles taken from these three
models relative to wild type controls using high density oligonucleotide arrays. All microarray comparisons were made with
at least 3 animals in each condition, and only those genes having at least 2-fold difference and whose coefficient of variance
was less than 100% were considered to be differentially expressed. When considered globally, there was a similar overlap in
gene changes between the 3 models: 19% between HSA-AR and AR97Q, 21% between AR97Q and AR113Q, and 17%
between HSA-AR and AR113Q, with 8% shared by all models. Several patterns of gene expression relevant to the disease
process were observed. Notably, patterns of gene expression typical of loss of AR function were observed in all three
models, as were alterations in genes involved in cell adhesion, energy balance, muscle atrophy and myogenesis. We
additionally measured changes similar to those observed in skeletal muscle of a mouse model of Huntington’s Disease, and
to those common to muscle atrophy from diverse causes.
Conclusions/Significance: By comparing patterns of gene expression in three independent models of KD/SBMA, we have
been able to identify candidate genes that might mediate the core myogenic features of KD/SBMA.
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Introduction
Kennedy disease/spinal bulbar muscular atrophy (KD/SBMA),
is a progressive neuromuscular disease [1,2], which is caused by an
expanded trinucleotide repeat length encoding the polyglutamine
(polyQ) tract of the androgen receptor (AR) gene [3]. Polygluta-
mine expansion of other genes similarly results in neurodegener-
ative conditions, such as Huntington’s disease and several
autosomal dominant spinocerebellar ataxias [4]. The mechanisms
that mediate neurodegeneration in the polyQ diseases remain
poorly understood. The orthodox view of KD/SBMA is that the
polyQ expanded AR has a toxic gain of function and also a loss of
trophic function within motoneurons, resulting in neuron loss and
consequently denervation-induced muscular atrophy. However,
recent insight from mouse models of KD/SBMA have suggested
that primary myogenic pathology, and more specifically patho-
logical alterations in gene expression within skeletal muscle, might
also contribute to this disease (reviewed in [5]). This evidence
consists mainly of 2 major findings: that myopathy precedes
neuropathy in mice with genetic polyQ expansion mutations in the
AR [6], and also that overexpression of AR in muscle fibers is
sufficient to reproduce several hallmark features of KD/SBMA
[7]. Additional circumstantial evidence includes the presence of
myopathy and transcriptional alterations in polyQ expanded AR
mutant mice [6,7,8,9], and studies of human pathology [6,10,11].
Transcriptional disturbance caused by polyQ expansion is
thought to contribute to the etiology of KD/SBMA. Loss of the
normal transcriptional functions of AR [12,13], is paired with gain
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12922of toxic function, in which novel interactions of AR with cofactors
results in aberrant transcriptional activation and/or repression
[14]. An additional possibility is that transcriptional disturbance
might occur indirectly, due to pathology at the cellular, tissue,
organ or system level [5]. For example, muscle from polyQ AR
mutant mice exhibit alterations in gene expression typical of
denervation [6,7,15], which seems likely to originate as a cell non-
autonomous response to neuropathy. Other candidate genes
which might mediate pathology in KD/SBMA have been
identified, including vascular endothelial growth factor (Vegfa)
[7,9], P300/CREB binding protein (P300/CBP) [9,16], heat shock
proteins [17,18,19,20,21,22,23,24], and genes related to mito-
chondrial function [25]. More systematic studies of gene
expression have been performed on cell lines [14], but to date,
there have been no published reports of transcriptional profiling of
mouse models of KD/SBMA.
Research into the etiology of KD/SBMA has been hampered
somewhat by mouse models being analyzed individually, with little
or no direct comparison between models. We therefore included
several mouse models that differ significantly in the type of
induced mutation and in some features of their phenotype
(reviewed in [5]), but share common pathological features,
including: myopathy, neuropathy, sex biased neuromuscular
atrophy, ligand-dependant pathology, and transcriptional distur-
bance. HSA-AR mice, which lack polyQ AR despite having these
features of KD/SBMA pathology, were included in the compar-
ison to allow us to evaluate those alterations which are unique to
polyQ AR. Additionally, we compared these results with published
microarray analysis of gene expression in skeletal muscle of mice
with related conditions, such as AR knock out (ARKO, [26]),
DHT treatment of mice [27,28], Huntington’s disease [29],
denervation induced and chronic muscle wasting [15,30] to gain
insight into the underlying systemic, cellular and molecular
pathological mechanisms.
Results
Complete lists of differentially regulated genes resulting from
microarray analysis of HSA-AR, AR97Q and AR113Q are
presented in the supporting material (Tables S1, S2, S3). The
degree to which genes are regulated similarly between these
models is represented by Venn diagram (Figure 1). This analysis
indicated a similar degree of overlap between the 3 models, and
suggested that a core pattern of altered gene expression is
associated with the symptoms of KD/SBMA common to the three
models. The list of genes in the intersection between the 3 models
is reported in Table S4.
The list of candidate genes presented in Table S4 notably
includes several whose functions relate to differentiation and/or
atrophy of muscle. These include: DNA-damage-inducible
transcript 4-like (Ddit4l), Enabled homolog (Enah), F box protein
32 (Fbxo32), and Integrin beta 1 binding protein 3 (Itgb1bp3). Other
differentially regulated genes are implicated in regulating oxidative
metabolism within skeletal muscle including: Ddit4l, Phospholipase
A2, group VII (Pla2g7), and Phosphorylase kinase alpha 1 (Phka1).
Ddit4l, also known as REDD2 and SMHS1, inhibits muscle
growth via the Igf1/mTOR pathway and is regulated during
atrophy of rat soleus muscle and the associated fiber type transition
from oxidative to glycolytic [31,32]. Enah, also known as MENA,
modulates the actin cytoskeleton and cell signaling along with
VASP. Dominant negative inhibition of both Enah and VASP
results in cardiomyopathy [33]. Itgb1bp3, also known as MIBP, is
developmentally regulated during myogenic differentiation and is
thought to inhibits myocyte adhesion to laminin and myocyte
production of laminin [34,35]. Allelic variants of Pla2g7 can
promote reductions in adiposity following exercise in human
populations [36], and reduction of adipose tissue is a known
function of myocyte AR [37]. Allelic variants in Phka1 in human
populations are associated with metabolic myopathy [38,39].
When considered in the context of the putative protective or toxic
functions of these genes, the general pattern of regulation observed
in our samples for Ddit4l, Enah and Itgb1bp3 are consistent with
adaptive tissue response to toxicity and that observed for Phka1
and Pla2g7 is consistent with a causal role in myopathy.
Figure 1. Venn diagrams of microarray results by mouse
model. Diagram representing the number of genes whose expression
differed from WT controls for each mutant strain (HSA-AR, AR97Q,
AR113Q), and the number of such genes shared by each model.
Notably, the overlap between HSA-AR and either of the polyQ models
was similar to the overlap between the polyQ AR samples. Gene
numbers were obtained by examining gene lists generated by a 2-fold,
p#0.05 criterion.
doi:10.1371/journal.pone.0012922.g001
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pattern of gene expression which is associated with diverse forms
of muscle wasting [15,30,40]. Because muscle wasting is a cardinal
feature of KD/SBMA and wasting is present in all 3 models, we
were not surprised to find Fbxo32 in all of the gene lists (Table S4
and Table 1) However, Fbxo32 was unexpectedly decreased in all 3
models, whereas increases in Fbxo32 were observed in other cases
of muscle wasting, including diabetes, renal failure, cancer and
denervation [15,30]. Nonetheless, genes thought to be down-
stream from Fbxo32 were also found to be affected in a manner
consistent with studies of muscle atrophy (Table S4 and S5),
suggesting a non-canonical activation of this pathway. In other
words, these results suggest that muscle atrophy in KD/SBMA
may not be not triggered by increases in Fbxo32, but rather that
genes downstream of this ubiquitin ligase may mediate atrophy.
Our analysis also indicates patterns of gene expression
associated exclusively with polyQ AR, and maybe associated with
symptoms that are found in those models but not HSA-AR (e.g.
AR-immunoreactive nuclear inclusions, which are not observed in
HSA-AR [41]). The list of genes in the intersection between the
polyQ models (AR97Q and AR113Q) is reported in Table 2. With
this comparison, we observed several previously identified
candidate polyQ genes in our lists, including DnaJ (Hsp40)
homolog, subfamily B, member 6 (Dnajb6) and P300/CBP-
associated factor (Pcaf, Table S5). Dnajb6, also known as MRJ
and its drosophila ortholog, can suppress polyglutamine toxicity and
aggregate formation in vitro and in flies [42,43]. The histoacetyl-
transferase Pcaf associates with polyQ AR and is found in
aggregates in polyQ AR-expressing cells in vitro [44]. For both
Dnajb6 and Pcaf, the observed pattern is consistent with a
protective function of altered mRNA expression within the skeletal
muscle of the polyQ AR mice. We also observed similarity
between our models and gene expression in skeletal muscle of a
mouse model of Huntington’s disease [29], although these
similarities were not entirely limited to polyQ AR mice (Tables
S4 and S5). This is significant, as Huntington’s disease shares
several similarities with KD/SBMA: it is also caused by
polyglutamine expansion mutations [4], and neuromuscular
pathology, including alterations in skeletal muscle gene expression
are observed in mouse models of this disease [29,45].
Loss of AR function is thought to contribute to atrophy in KD/
SBMA, as is illustrated by the advanced atrophy of polyQ AR
mutant mice on a loss of AR function testicular feminization
mutation (Tfm) genetic background [12]. The mechanism of the
protective actions of AR in this regard are not currently
understood, but might involve stimulation of trophic factor
production [9], or activation of the Insulin-like growth factor1
(Igf1) pathway [40], for example. Some support for this idea was
Table 1. Validation of the results of microarray experiments by qRT-PCR analysis.
Microarray Fold Change Relative to WT qRT-PCR Fold Change Relative to WT (P-value)
Unigene
Symbol HSA-AR AR97Q AR113Q HSA-AR AR97Q AR113Q
Vegfa 21.86 25.11 22.22 21.74 (0.01) 22.35 (0.03) 21.92 (0.02)
Fbxo32 23.46 26.69 26.67 22.56 (0.03) 22.78 (0.05) 23.03 (0.02)
Itgb1bp3 24.99 280.73 218.48 25.26 (0.05) 233.33 (,0.01) 27.69 (0.04)
Zmnd17 29.47 28.79 232.22 24.76 (0.01) 225.00 (0.04) 233.33 (,0.01)
Gbe1 4.84 2.68 4.05 2.38 (0.05) 5.41 (,0.01) 2.81 (0.04)
Ankrd1 15.69 16.68 6.11 45.51 (0.04) 28.55 (,0.01) 6.81 (0.01)
All samples were compared with their WT controls to evaluate fold change. The expression of each test gene was normalized to the level of GAPDH within each sample
prior to comparisons between samples. Each group represents samples from 3 mice.
doi:10.1371/journal.pone.0012922.t001
Table 2. Functional distributions of regulated genes in some clusters by Database for Annotation Visualization and Integrated
Discovery (DAVID) analysis.
Pattern of Regulation Functional Groupings P-value
Down in all models Protein modification, Phosphate metabolism, Endoplasmic reticulum, Regulation of neurogenesis, Glycerol metabolism,
Amino acid metabolism, Calmodulin binding, Magnesium ion binding, Regulation of protein kinase activity
0.0466
Up in all models Intracellular organelle, Transcription cofactor activity, Focal adhesion, I band 0.0481
Down in PolyQ models Metal ion binding, Steroid metabolism, Sarcomere, Muscle contraction, Filamentous actin, Endocytosis, Chemical
homeostasis, Macrophage activation, Membrane fraction
0.0408
Up in PolyQ models Hydrolase activity, Protein binding, Peptidase activity 0.0356
Down in HSA-AR Protein modification, Metal ion binding, Muscle contraction, Kinase activity, Neuron projection,
Actin cytoskeleton, Mitochondrion, Phosphotransferase activity, Glucose metabolism
0.0563
Up in HSA-AR Protein metabolism, I band, Response to stress, Kallikrein activity, Induction of apoptosis, Zinc ion binding,
Calcium ion binding, Transcription factor binding, Actin cytoskeleton
0.0639
Functional analysis of regulated genes was performed using Functional Annotation Tool (DAVID Bioinformatics Resources) according to GO term (biological process,
molecular function and cellular component) on several clusters: cluster 8 which was down in all models, cluster 15 which was up in all models, clusters 2 and 7 which
were down in polyQ models only, cluster 14 which was up in polyQ models only, cluster 4 which was up only in HSA-AR and clusters 10 and 11 which were up only in
HSA-AR.
doi:10.1371/journal.pone.0012922.t002
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muscle all 3 lines using qPCR (Table 1) and in the polyQ lines
using microarray (Table S5). We did not find that Igf1 was
reduced, nor was the Igf1 signaling pathway obviously dysregu-
lated, with the exception of Insulin-like growth factor binding
protein 5 (Igfbp5), which was decreased in AR97Q and AR113Q
(Table S5). It remains possible that Igf1 is decreased at the protein
level.
We extended this comparison of our three models by
performing a hierarchical cluster analysis in an effort to further
reduce the list of candidate genes (Figure 2). We found that 2
clusters of coregulated genes (cluster 8 and 15) are shared among
all three models. Functional analysis of these coregulated clusters
can be found in Tables 2 and 3. Analysis of gene ontogeny (GO)
terms in coregulated clusters indicated diverse classes of biological
functions of regulated genes, including several effects on protein
metabolism, ion binding and cellular differentiation (Table 2).
Interestingly, decreases in genes mediating metal ion binding were
observed in both clusters unique to PolyQ models and HSA-AR,
suggesting a convergence of gene function, despite different
clustered genes. Kyoto encyclopedia of genes and genomes
(KEGG) analysis of coregulated clusters indicated effects on the
insulin signaling pathway as well as several cell adhesion and cell
signaling pathways (Table 3). Insulin signaling has not previously
been examined in KD/SBMA, but disturbance in mitochondria
[25] could certainly result from alterations in insulin signaling
[46,47]. Similarly, alterations in cellular differentiation or tissue
remodeling associated with muscle pathology could presumably
account for the preponderance of these pathways.
Microarray results were validated using quantitative reverse
transcription polymerase chain reaction (qRT-PCR) for 6 genes
that were changed in all three models. Genes were chosen from
microarray results to represent both increased and decreased
expression and also representing a range of expression level
changes. Results of qRT-PCR agreed very well with microarray
results (Table 1). In each of the 18 tests performed, consistent
changes in gene expression were observed. These results lead us to
conclude that our microarray experiments accurately reflect the
gene expression changes occurring in the different disease models.
Discussion
This report characterizes the transcriptome of skeletal muscle in
three independently generated mouse models of KD/SBMA. This
study was undertaken to shed light on emerging evidence of
myogenic contributions to KD/SBMA (reviewed in [5]). We were
specifically interested in identifying patterns of gene expression
that are shared between the 3 models, and might therefore
account for the muscle wasting, motor axon loss and histopathol-
ogy typical of KD/SBMA. By comparing results obtained in three
models, we were able to greatly reduce the number of candidate
genes.
It was surprising to find that Fbxo32 expression was reduced in
all models, as this is a prime candidate gene for muscle atrophy.
However, several putative downstream effectors of Fbxo32 were
regulated similarly to other cases of muscular atrophy. Certainly
there is precedent for uncoupling within the Fbxo32 signaling
pathway within myocytes [48]. One potential explanation of this
observation is that preserved androgen functions in muscle repress
Fbxo32, but that other cellular pathology initiates the pathway via
alternate mechanisms. Consistent with this idea, testosterone
decreases Fbxo32 in rat levator ani muscle [49], and further loss of
AR function in mouse models of KD/SBMA accelerates
pathology [12]. A final possibility is that Fbxo32 is indeed involved,
but is activated by post-translational modification rather than
transcriptional induction.
As we have discussed elsewhere [5,7], it is surprising that
overexpression of WT AR can reproduce some of the effects of
polyQ expansion of AR. Aside from the implication that a polyQ
expansion is not necessary for pathology, this observation is
Figure 2. Hierarchical cluster analysis of gene expression in the 3 mouse models. Cluster output represents colorimetrically indicated log2
ratio change. Mutant strains are represented by columns and rows represent a single gene. Clusters of co-regulated genes are labeled. Most clusters
are unique to one of the mutant strains. Only cluster 8 and 15 show similar patterns across the 3 models, and clusters 7 and 14 are similar in the polyQ
models but not HSA-AR.
doi:10.1371/journal.pone.0012922.g002
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whereas overexpression of WT AR would be expected to increase
AR signaling. We were therefore interested in comparing polyQ
AR and HSA-AR models. We find that the overlap between HSA-
AR and both AR97Q and AR113Q is comparable to the overlap
between the polyQ AR models in terms of the number of genes
differentially regulated in any pair-wise comparison (Figures 1 and
2). Moreover, a total of 43 genes (or 20–25% of the genes for a
give model) were differentially regulated in all three models. We
also examined our results for evidence of loss of AR function by
comparing our gene lists with those reported for ARKO muscle
[26]. As expected, several polyQ AR genes are also altered in
ARKO muscle (Table S5). Surprisingly, HSA-AR samples also
exhibit alterations in gene expression similar to those observed in
ARKO muscle (Table S4), with gene regulation in the same
direction, suggesting that a paradoxical loss of AR function may
result from AR overexpression. This loss of function might result
from disturbance in other components of the AR signaling
pathway (e.g. titration of cofactors), or might reflect indirect effects
on gene expression resulting from muscle growth, for example.
Nonetheless, some of the differentially regulated genes were
shared by AR97Q and ARQ113 models but not HSA-AR (Table
S5). It is tempting to speculate that this intersection includes genes
that mediate aspects of KD/SBMA that are unique to polyQ
expansion of AR. Notably, protein misfolding [50], aberrant
proteolysis of polyQ AR [51,52,53] and aberrant interactions with
Heat shock proteins [19,20,21,23,54,55,56], have all been
implicated in polyQ-specific features of this disease, whereas we
find no evidence of AR aggregates in HSA-AR mice [41].
One notable limitation of the current study is uncertainty
concerning the androgen-dependence of the observed alterations
in gene expression. Because all subjects were unmanipulated adult
males, we cannot be certain that observed effects result from
testosterone action, or if so, whether ongoing stimulation with
testosterone is required for the alterations gene expression. We are
therefore conducting experiments to evaluate this possibility by
performing microarray analysis of skeletal muscle from female
HSA-AR mice which are treated acutely with testosterone to
induce KD/SBMA symptoms [7,57].
Materials and Methods
Animals
Ten WT C57BL/6J mice (5 males and 5 females, 70 days old)
from Jackson Laboratories were used to make the RNA reference
samples.
Three mouse models of KD/SBMA were used in the current
study: HSA-AR [7], AR113Q [6,58], and AR97Q [59]. Two of
the three models,, AR97Q and AR113Q, have a polyQ expansion
in the AR. HSA-AR are transgenic (Tg) mice that overexpress
selectively in skeletal muscle a rat AR with a WT number (24) of
glutamine repeats [7]. AR97Q are Tg mice that express human
AR under the control of a bactin/CMV promoter [59]. AR-113Q
are knock-in mice in which the first exon of the endogenous mouse
AR has been replaced with a similar sequence from the human
AR containing 113 glutamine repeats [6].
HSA-AR: The production, genotyping and phenotyping of
HSA-AR transgenic mice has been described elsewhere [7]. Two
founding lines (L78 and L141) of HSA-AR mice, that differ in the
copy number of the transgene and have corresponding differences
in the severity of the neuromuscular atrophy (L178,L141) have
been previously characterized. In this study, Tg male mice from
L141 (n=5) and their WT brothers (n=8, all mice were 110–130
days of age) were used. Behavioral, histological and candidate gene
expression data have been previously reported for a subset of these
animals [7].
AR113Q: The production and genotyping of AR113Q Knock In
mice has been described elsewhere [58], as has their neuromuscular
phenotype [6]. Mutant males (n=3, 3–4 months of age), fully
backcrossed onto the C57BL/6J strain, were used in this study.
AR97Q: The production, genotyping and phenotyping of
AR97Q Tg mice has been described elsewhere [59]. Tg AR97Q
males and WT brothers (n=6 of each, 112–118 days old) were
used in this study.
All animal experiments conformed to NIH guidelines and were
approved by the University Animal Care Committee of the
University of Toronto Mississauga (Approved protocol #
20007262).
Tissue Harvesting and Extraction of RNA
Under surgical anesthesia, limb muscles were dissected,
harvested, and immediately frozen in liquid nitrogen before
storage at 280uC. Frozen limb muscles were placed in TRizol
Reagent (Life Technologies, NY) and homogenized before RNA
extraction. The total RNA extraction was performed according to
the manufacturer’s guidelines. After extraction, an aliquot was
used to confirm sample integrity by electrophoresis of glyoxylated
RNA through 1.2% agarose gel and visualization by staining with
ethidium bromide. RNA was quantified using a Nanodrop (Fisher
Scientific) spectrophotometer.
Sample Labelling, Microarray Hybridization and Data
Analysis
Two-color microarray experiments were performed using
38.5K oligo mouse MEEBO arrays (Mouse Ready Arrays,
Table 3. KEGG analysis of gene pathways for shared clusters.
Pathway HSA-AR gene # P-value AR97Q gene # P-value AR113Q gene # P-value
Insulin signaling pathway 9 0.0017 9 0.0034 4 0.1996
Focal adhesion 8 0.0420 8 0.0686 6 0.0680
Adherens Junction 4 0.1289 5 0.0500 4 0.0526
Regulation of actin cytoskeleton 6 0.2714 9 0.0398 4 0.4295
Calcium signaling pathway 7 0.0723 9 0.0159 3
MAPK signaling pathway 2 10 0.0460 4
Complete gene lists resulting from microarray analysis of each model were separately analyzed with DAVID and the resulting KEGG pathways and associated p-values of
obtaining these pathways by chance are represented. The number of hits was determined from the gene lists manually.
doi:10.1371/journal.pone.0012922.t003
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oligonucleotide (70mer) probes is largely derived from constitu-
tively expressed exons and represents approximately 25,000 mouse
genes.
Cyanine dyes were directly incorporated into cDNA synthesized
from total RNA following the procedure of Neal et al. (2003).
Briefly, 38 ml reactions containing 20 mg of total RNA, 500 mmol/L
of dATP, dGTP and dTTP; 50 mmol/L dCTP (GE Life Sciences),
25 mmol/L Cy3- or Cy5-dCTP (Perkin Elmer), 10 mmol/L DTT
and 150 pmol oligo dT20 primer were heated to 65uC for 5 min,
then 42uC for 5 min. 2 ml SuperScript II reverse transcriptase
(Invitrogen Corporation) was added, and cDNA synthesis was
carried out for 3 h at 42uC. Reactions were stopped by the addition
of 5 mL of 50 mmol/L EDTA. RNA was hydrolyzed with 4 mLo f
5 mol/L NaOH for 10 min at 65uC, and the reaction was then
neutralized by titration with acetic acid. The cDNA from one
Cyanine-3 (Perkin Elmer, Boston, MA) reaction (reference sample)
were combined with those from a Cyanine-5 (Perkin Elmer, Boston,
MA) reaction (experiment sample) and were co-hybridized to oligo
array. Images of the hybridized arrays were acquired using a
ScanArray 4000 XL laser scanner (Perkin Elmer, Boston, MA) and
fluorescent intensities from spots were quantified using GenePix 5
software (Axon Instruments, Inc., CA).
Microarray images and quantification data were then imported
into GeneTraffic DUO (Stratagene, La Jolla, CA) for analysis. The
datawerenormalizedusingtheLowessalgorithmatthesubgrid level
while ignoring flagged values. After normalization of the data, lists of
differentially expressed genes were obtained using GeneTraffic.
For the HSA-AR and AR113Q samples, a universal RNA
reference sample made from C57BL/6J mice was utilized on each
array. Triplicate arrays using RNA samples from the different
experimental animals (i.e. HSA-AR Tg males, AR113Q Tg
males,and WT brothers) were performed such that 3 animals in
each mutant genotype were compared to WT controls. Log2 ratios
of experimental (either mutant or their WT brothers) samples
(Cy5) versus reference RNA (Cy3) were obtained. The log2 ratios
from mutant samples were then subtracted from log2 ratios from
WT versus reference RNA controls to find differentially regulated
genes. Gene lists were filtered in GeneTraffic to include only those
genes that displayed at least 2-fold difference and whose coefficient
of variance was less than 100% and had a p-value less than 0.05
using a T-test.
Subsequent to the initial experiments described above, the
AR97Q model became available. However, since there were not
sufficient amounts of the Universal RNA reference remaining,
triplicate arrays using different biological replicates of the AR97Q
males (experimental, Cy5) were directly compared with their WT
brothers (reference, Cy3). Dye swap experiments were not
performed as previous experiments in our lab had demonstrated
that they do not alter the lists of differentially expressed genes very
much (Neal et. al., 2003). Using GeneTraffic, lists of genes that
displayed at least 2-fold difference and whose coefficient of
variance was less than 100% were made.
Hierarchical cluster analysis were performed in GeneTraffic
DUO using the Pearson algorithm and average linkage [60].
Cluster figures were made using the MultiExperiment Viewer
(MeV) in the TM4 suite of software tools (www.tm4.org) (Saeed
et al., 2006).
All microarray data is MIAME compliant and has been
deposited in GEO (accession number GSE10190).
Real Time Quantitative RT-PCR
For the quantitative PCR (qRT-PCR) analysis, the 3 biological
samples of each genotype used for the microarray analysis plus
additional biological samples were used. For the HSA-AR male
mice, 2 additional mice were analyzed (5 mice total). For the
AR97Q and their WT controls, 3 additional mice were analyzed
(6 mice total for each). For the AR113Q males, only the original 3
biological replicates were analyzed. In addition to the biological
replicates, 2 or 3 technical replicates of each biological sample
were performed. A two-step approach was taken in which the
initial reverse transcription was followed by the qRT-PCR
amplification After DNase I (Invitrogen Corporation, CA)
treatment, DNA-free total RNA was reverse transcribed using a
dT20VN primer (Sigma, Oakville, ON) with SuperScript II. Each
RNA reaction had a control reaction without reverse transcriptase
to evaluate any genomic DNA contamination. Two ml of the
diluted reaction was used as template for each 25 mL RT-PCR
amplification. Reactions were assembled using SYBRH Green
JumpStart Taq ReadyMix (Sigma, Oakville, ON). The Mx4000
Multiplex Quantitative PCR System (Stratagene, La Jolla, CA)
was used for data acquisition and analysis according to the
instructions of the manufacturer. Samples were incubated at 95uC
for 10 min prior to thermal cycling (40 cycles of: 95uC for 30 s,
57uC for 30 s, and 72uC for 30 s). In order to confirm the
amplification specificity and identity the PCR products, a melting
curve analysis between 55uC and 95uC was also carried out using
the Mx4000 software. The completed reactions were heated to
95uC for 1 min and cooled to 55uC and reactions were re-heated
in 1uC increments back to 95uC in order to plot a dissociation
curve. After exporting the ROX-normalized fluorescence mea-
surements to Microsoft Excel, the program LinRegPCR [61] was
used to determine the efficiency of each reaction. These
efficiencies were used in the final calculation of fold induction
from the DCt values and the expression of each test gene was
normalized to the level of glyceraldehyse 39 dehydrogenase
(GAPDH) within each sample prior to comparisons between
samples.
Primer Design
The cDNA sequences for the genes, AR, GAPDH, Fbxo32 (F-box
protein 32), Vegfa (Vascular endothelial growth factor), Ankrd1
(Ankyrin repeat domain 1), Itgb1bp3 (integrin beta 1 binding
protein 3), Zmynd17 (Zinc finger, MYND domain containing 17),
Gbe1 (Glucan (1,4-alpha-), branching enzyme 1), Igf1 (Insulin-like
growth factor 1), Akt1 (Thymoma viral proto-oncogene 1) and
MuRF1 (Tripartite motif-containing 63) were obtained from public
databases. PCR primers were designed from the corresponding
cDNA sequences using the Whitehead Institute’s Primer3 software
[62]. All oligonucleotide sequences and primer pairs were checked
with OligoAnalyzer 3.0 (http://scitools.idtdna.com/Analyzer/)
for secondary structure and dimer formation. Each primer and
amplicon sequence was tested using the nucleotide-nucleotide
BLAST alignment tool to ensure minimal similarity with any other
sequence. Oligonucleotide primers were obtained from Invitrogen.
Primer sequences used in this study can be found in Table S6.
Supporting Information
Table S1 Complete gene list for HSA-AR. Genes regulated in
HSA-AR muscle are presented. For inclusion, each gene had to
appear in the gene list generated by a 2 fold change, p#0.05
criteria. Fold change values relative to WT controls are presented,
as are Genbank accession numbers, unigene symbols and names.
Found at: doi:10.1371/journal.pone.0012922.s001 (0.04 MB
XLS)
Table S2 Complete gene list for AR97Q. Genes regulated in
AR97Q Tg muscle are presented. For inclusion, each gene had to
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criteria. Fold change values relative to WT controls are presented,
as are Genbank accession numbers, unigene symbols and names.
Found at: doi:10.1371/journal.pone.0012922.s002 (0.05 MB
XLS)
Table S3 Complete gene list for AR113Q. Genes regulated in
AR113Q muscle are presented. For inclusion, each gene had to
appear in the gene list generated by a 2 fold change, p#0.05
criteria. Fold change values relative to WT controls are presented,
as are Genbank accession numbers, unigene symbols and names.
Found at: doi:10.1371/journal.pone.0012922.s003 (0.04 MB
XLS)
Table S4 Gene list common to all models. Genes regulated in all
3 models are presented. For inclusion, each gene had to appear in
the gene list generated by a 2 fold change, p#0.05 criteria in all
models. Fold change values are presented for each model as are
Genbank accession numbers, unigene symbols and names. In
addition, genes that have been reported to be regulated in skeletal
muscle of related conditions are identified: ARKO=genes also
identified in microarray analysis of skeletal muscle of AR null
mice, Atrophy=genes also identified in microarray analysis of
skeletal muscle of diverse conditions resulting in muscular atrophy,
DHT=genes also identified in serial analysis of gene expression
(SAGE) of skeletal muscle of mice treated with dihydrotestoster-
one, HD=genes also identified in microarray analysis of skeletal
muscle of mouse model of Huntington’s disease.
Found at: doi:10.1371/journal.pone.0012922.s004 (0.02 MB
XLS)
Table S5 The list of up- and down-regulated genes found only in
PolyQ models. Genes regulated in all 3 models are presented. For
inclusion, each gene had to appear in the gene list generated by a 2
fold change, p#0.05 criteria in AR97Q and AR113Q models.
Fold change values are presented for each model as are Genbank
accession numbers, unigene symbols and names. In addition,
genes that have been reported to be regulated in skeletal muscle of
related conditions are identified: ARKO=genes also identified in
microarray analysis of skeletal muscle of AR null mice,
Atrophy=genes also identified in microarray analysis of skeletal
muscle of diverse conditions resulting in muscular atrophy,
HD=genes also identified in microarray analysis of skeletal
muscle of mouse model of Huntington’s disease.
Found at: doi:10.1371/journal.pone.0012922.s005 (0.02 MB
XLS)
Table S6 List of primers used for quantitative RT-PCR
validation of microarray results.
Found at: doi:10.1371/journal.pone.0012922.s006 (0.02 MB
XLS)
Acknowledgments
We are extremely grateful to Canadian Drosophila Microarray Center
(CDMC) for providing microarray facilities.
Author Contributions
Conceived and designed the experiments: KM HA JTW DAM. Performed
the experiments: KM ZR. Analyzed the data: KM ZR DAM. Contributed
reagents/materials/analysis tools: KM ZR PR ZY HA MK GS AL JTW.
Wrote the paper: KM ZR PR ZY HA MK GS AL JTW DAM.
References
1. Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar
muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18: 671–680.
2. Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, et al. (2006) Natural history
of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients.
Brain 129: 1446–1455.
3. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991)
Androgen receptor gene mutations in X-linked spinal and bulbar muscular
atrophy. Nature 352: 77–79.
4. Zoghbi HY, Orr HT (2000) Glutamine repeats and neurodegeneration. Annu
Rev Neurosci 23: 217–247.
5. Monks DA, Rao P, Mo K, Johansen JA, Lewis G, et al. (2008) Androgen
receptor and Kennedy disease/spinal bulbar muscular atrophy. Horm Behav 53:
729–740.
6. Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, et al. (2006) Androgen-
dependent pathology demonstrates myopathic contribution to the Kennedy
disease phenotype in a mouse knock-in model. J Clin Invest 116: 2663–2672.
7. Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, et al. (2007)
Overexpression of wild-type androgen receptor in muscle recapitulates
polyglutamine expansion. Proc Natl Acad Sci U S A 104: 18259–18264.
8. Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, et al. (2006) Pathogenesis,
animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).
Exp Neurol 200: 8–18.
9. Sopher BL, Thomas PS, Jr., LaFevre-Bernt MA, Holm IE, Wilke SA, et al.
(2004) Androgen Receptor YAC Transgenic Mice Recapitulate SBMA Motor
Neuronopathy and Implicate VEGF164 in the Motor Neuron Degeneration.
Neuron 41: 687–699.
10. Katsuno M, Adachi H, Sobue G (2003) Spinal and Bulbar Muscular Atrophy:
Clinical Features and Pathogenesis. ACNR 3: 8–12.
11. Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, et al. (2007) Pathogenesis
and molecular targeted therapy of spinal and bulbar muscular atrophy.
Neuropathol Appl Neurobiol 33: 135–151.
12. Thomas PS, Jr., Fraley GS, Damian V, Woodke LB, Zapata F, et al. (2006) Loss
of endogenous androgen receptor protein accelerates motor neuron degenera-
tion and accentuates androgen insensitivity in a mouse model of X-linked spinal
and bulbar muscular atrophy. Hum Mol Genet 15: 2225–2238.
13. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, et al. (2000) CREB-
binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9:
2197–2202.
14. Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH (2002)
Altered transcriptional regulation in cells expressing the expanded polyglutamine
androgen receptor. Hum Mol Genet 11: 1967–1976.
15. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, et al. (2007) Rapid
disuse and denervation atrophy involve transcriptional changes similar to those
of muscle wasting during systemic diseases. FASEB J 21: 140–155.
16. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, et al. (2004) Sodium
butyrate ameliorates phenotypic expression in a transgenic mouse model of
spinal and bulbar muscular atrophy. Hum Mol Genet.
17. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, et al. (1999)
Polyglutamine-expanded androgen receptors form aggregates that sequester heat
shock proteins, proteasome components and SRC-1, and are suppressed by the
HDJ-2 chaperone. Hum Mol Genet 8: 731–741.
18. Walcott JL, Merry DE (2002) Ligand promotes intranuclear inclusions in a novel
cell model of spinal and bulbar muscular atrophy. J Biol Chem 277:
50855–50859.
19. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, et al. (2000) Chaperones
Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured
neuronal cells expressing truncated androgen receptor protein with expanded
polyglutamine tract. J Biol Chem 275: 8772–8778.
20. Bailey CK, Andriola IF, Kampinga HH, Merry DE (2002) Molecular
chaperones enhance the degradation of expanded polyglutamine repeat
androgen receptor in a cellular model of spinal and bulbar muscular atrophy.
Hum Mol Genet 11: 515–523.
21. Ishihara K, Yamagishi N, Saito Y, Adachi H, Kobayashi Y, et al. (2003)
Hsp105alpha suppresses the aggregation of truncated androgen receptor with
expanded CAG repeats and cell toxicity. J Biol Chem 278: 25143–25150.
22. Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB, et al. (2006)
Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces
aggregation and promotes degradation of the expanded glutamine androgen
receptor without stress protein induction. Hum Mol Genet 15: 1876–1883.
23. Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, et al. (2005)
Pharmacological induction of heat-shock proteins alleviates polyglutamine-
mediated motor neuron disease. Proc Natl Acad Sci U S A 102: 16801–
16806.
24. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, et al. (2005) 17-
AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron
degeneration. Nat Med 11: 1088–1095.
25. Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, et al.
(2009) Mitochondrial abnormalities in spinal and bulbar muscular atrophy.
Hum Mol Genet 18: 27–42.
26. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA, et al. (2008) Impaired
skeletal muscle development and function in male, but not female, genomic
androgen receptor knockout mice. FASEB J 22: 2676–2689.
Muscle Genes in KD/SBMA Mice
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e1292227. Yoshioka M, Boivin A, Bolduc C, St-Amand J (2007) Gender difference of
androgen actions on skeletal muscle transcriptome. J Mol Endocrinol 39:
119–133.
28. Yoshioka M, Boivin A, Ye P, Labrie F, St-Amand J (2006) Effects of
dihydrotestosterone on skeletal muscle transcriptome in mice measured by
serial analysis of gene expression. J Mol Endocrinol 36: 247–259.
29. Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, et al. (2005) Gene
expression in Huntington’s disease skeletal muscle: a potential biomarker. Hum
Mol Genet 14: 1863–1876.
30. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, et al. (2004) Multiple
types of skeletal muscle atrophy involve a common program of changes in gene
expression. Faseb J 18: 39–51.
31. Miyazaki M, Esser KA (2009) REDD2 is enriched in skeletal muscle and inhibits
mTOR signaling in response to leucine and stretch. Am J Physiol Cell Physiol
296: C583–592.
32. Pisani DF, Leclerc L, Jarretou G, Marini JF, Dechesne CA (2005) SMHS1 is
involved in oxidative/glycolytic-energy metabolism balance of muscle fibers.
Biochem Biophys Res Commun 326: 788–793.
33. Eigenthaler M, Engelhardt S, Schinke B, Kobsar A, Schmitteckert E, et al.
(2003) Disruption of cardiac Ena-VASP protein localization in intercalated disks
causes dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 285:
H2471–2481.
34. Li J, Rao H, Burkin D, Kaufman SJ, Wu C (2003) The muscle integrin binding
protein (MIBP) interacts with alpha7beta1 integrin and regulates cell adhesion
and laminin matrix deposition. Dev Biol 261: 209–219.
35. Li J, Mayne R, Wu C (1999) A novel muscle-specific beta 1 integrin binding
protein (MIBP) that modulates myogenic differentiation. J Cell Biol 147:
1391–1398.
36. Wootton PT, Flavell DM, Montgomery HE, World M, Humphries SE, et al.
(2007) Lipoprotein-associated phospholipase A2 A379V variant is associated
with body composition changes in response to exercise training. Nutr Metab
Cardiovasc Dis 17: 24–31.
37. Fernando SM, Rao P, Niel L, Chatterjee D, Stagljar M, et al. (2010) Myocyte
androgen receptors increase metabolic rate and improve body composition by
reducing fat mass. Endocrinology 151: 3125–3132.
38. Orngreen MC, Schelhaas HJ, Jeppesen TD, Akman HO, Wevers RA, et al.
(2008) Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase
deficiency? Neurology 70: 1876–1882.
39. Wuyts W, Reyniers E, Ceuterick C, Storm K, de Barsy T, et al. (2005)
Myopathy and phosphorylase kinase deficiency caused by a mutation in the
PHKA1 gene. Am J Med Genet A 133A: 82–84.
40. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, et al. (2007) Akt
blocks ligand binding and protects against expanded polyglutamine androgen
receptor toxicity. Hum Mol Genet 16: 1593–1603.
41. Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, et al. (2007)
Overexpression of wild-type androgen receptor in muscle recapitulates
polyglutamine disease. Proc Natl Acad Sci U S A 104: 18259–18264.
42. Chuang JZ, Zhou H, Zhu M, Li SH, Li XJ, et al. (2002) Characterization of a
brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and
toxicity independently. J Biol Chem 277: 19831–19838.
43. Fayazi Z, Ghosh S, Marion S, Bao X, Shero M, et al. (2006) A Drosophila
ortholog of the human MRJ modulates polyglutamine toxicity and aggregation.
Neurobiol Dis 24: 226–244.
44. Katsuno M, Adachi H, Minamiyama M, Waza M, Doi H, et al. Disrupted
transforming growth factor-beta signaling in spinal and bulbar muscular
atrophy. J Neurosci 30: 5702–5712.
45. Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, et al. (2004)
Progressive abnormalities in skeletal muscle and neuromuscular junctions of
transgenic mice expressing the Huntington’s disease mutation. Eur J Neurosci
20: 3092–3114.
46. Boirie Y, Short KR, Ahlman B, Charlton M, Nair KS (2001) Tissue-specific
regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin.
Diabetes 50: 2652–2658.
47. Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS (2003) Effect of
insulin on human skeletal muscle mitochondrial ATP production, protein
synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A 100: 7996–8001.
48. Tong JF, Yan X, Zhu MJ, Du M (2009) AMP-activated protein kinase enhances
the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/
Akt signaling in C2C12 myotubes. J Cell Biochem 108: 458–468.
49. Pires-Oliveira M, Maragno AL, Parreiras-e-Silva LT, Chiavegatti T,
Gomes MD, et al. Testosterone represses ubiquitin ligases atrogin-1 and
Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo. J Appl
Physiol 108: 266–273.
50. Thomas M, Yu Z, Dadgar N, Varambally S, Yu J, et al. (2005) The unfolded
protein response modulates toxicity of the expanded glutamine androgen
receptor. J Biol Chem 280: 21264–21271.
51. Merry DE, Kobayashi Y, Bailey CK, Taye AA, Fischbeck KH (1998) Cleavage,
aggregation and toxicity of the expanded androgen receptor in spinal and bulbar
muscular atrophy. Hum Mol Genet 7: 693–701.
52. Li M, Chevalier-Larsen ES, Merry DE, Diamond MI (2007) Soluble androgen
receptor oligomers underlie pathology in a mouse model of spinobulbar
muscular atrophy. J Biol Chem 282: 3157–3164.
53. Mandrusiak LM, Beitel LK, Wang X, Scanlon TC, Chevalier-Larsen E, et al.
(2003) Transglutaminase potentiates ligand-dependent proteasome dysfunction
induced by polyglutamine-expanded androgen receptor. Hum Mol Genet 12:
1497–1506.
54. Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, et al. (2003)
Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the
spinal and bulbar muscular atrophy transgenic mouse model by reducing
nuclear-localized mutant androgen receptor protein. J Neurosci 23: 2203–2211.
55. Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, et al. (2000)
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition
on protein aggregation in cellular models of Huntington’s disease. Proc Natl
Acad Sci U S A 97: 2898–2903.
56. Adachi H, Waza M, Tokui K, Katsuno M, Minamiyama M, et al. (2007) CHIP
overexpression reduces mutant androgen receptor protein and ameliorates
phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.
J Neurosci 27: 5115–5126.
57. Johansen JA, Yu Z, Mo K, Monks DA, Lieberman AP, et al. (2008) Recovery of
function in a myogenic mouse model of spinal bulbar muscular atrophy.
Neurobiol Dis.
58. Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, et al. (2006) Abnormalities
of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113
CAG knock-in mice reveal toxic effects of the mutant protein. Am J Pathol 168:
195–204.
59. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, et al. (2002) Testosterone
reduction prevents phenotypic expression in a transgenic mouse model of spinal
and bulbar muscular atrophy. Neuron 35: 843–854.
60. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:
14863–14868.
61. Ramakers C, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption-free
analysis of quantitative real-time polymerase chain reaction (PCR) data.
Neurosci Lett 339: 62–66.
62. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 132: 365–386.
Muscle Genes in KD/SBMA Mice
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12922